glp-1 candidates Principle of novel drug for the treatment of diabetes and What's next for GLP-1 innovation:

Campaigns that once felt edgy but acceptable may now require stronger vetting and more cautious creativity

Thus far, the binding poses of two full-length peptide-bound, active GLP-1R structures 3,4 and an active-like structure with a truncated peptide agonist (peptide 5) 12 have been detailed, as well as variable ligand-dependent ECD receptor conformations

Real weight loss can be more easily achieved by first improving your metabolic health

The NAION MCL follows a number of filings by plaintiffs who allege Ozempic and Wegovy caused permanent vision loss and cite recent research linking semaglutide to a significantly increased risk of non-arteritic anterior ischemic optic neuropathy

Press release, 1 July 2025

Clinicians who specialize in diabetes or obesity care are great options if available to you